Unlocking gene control mechanisms to develop small molecule therapies

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes.

Year Invested: 2016
Location: Cambridge, MA
Visit: www.fulcrumtx.com

Recent News

March 15, 2018
Fulcrum Therapeutics to Present at BioCentury’s Future Leaders in the Biotech Industry Conference

February 28, 2018
Fulcrum Therapeutics to Present at the 11th Annual Future of Genomic Medicine Conference

October 11, 2017
Fulcrum Therapeutics to Present at the 18th Annual Fragile X and Related Neurodevelopmental Disorders Workshop

Read More News

Associated Team Members

Philip Reilly, M.D., J.D.
Venture Partner

Mark Levin